Ensysce Biosciences Receives Second Nasdaq Delisting Notice for Equity Deficiency

summarizeSummary

Ensysce Biosciences received a second Nasdaq delisting notice, this time for failing to meet the $2.5 million stockholders' equity requirement, intensifying concerns about its financial viability and continued listing.

check_boxKey Events

• Second Nasdaq Delisting Notice

  The company received a notice from Nasdaq on May 21, 2026, for non-compliance with the $2.5 million stockholders' equity requirement (Rule 5550(b)(1)) as of March 31, 2026.

• Compliance Deadline

  Ensysce Biosciences must submit a plan to regain compliance by July 6, 2026. If accepted, an extension of up to 180 days from May 21, 2026, may be granted.

• Intensified Financial Distress

  This notice follows a previous delisting warning for low stock price and recent disclosures of a 'going concern' warning and critical cash shortage, underscoring severe financial challenges.

auto_awesomeAnalysis

Ensysce Biosciences faces a critical threat to its Nasdaq listing, having received a second delisting notice, this time for failing to meet the $2.5 million stockholders' equity requirement. This follows a previous notice for its stock price falling below $1.00 and recent disclosures of a 'going concern' warning and cash shortage. The company must submit a plan to Nasdaq by July 6, 2026, to avoid delisting, highlighting severe financial distress and increasing the urgency for its announced strategic alternatives review.